New Zealand markets closed

Agenus Inc. (AGEN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
4.0100-1.1200 (-21.83%)
At close: 4:00PM EDT
3.9900 -0.02 (-0.50%)
After hours: 07:58PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close5.1300
Open4.0200
Bid3.9800 x 4000
Ask3.9700 x 1400
Day's range3.4601 - 4.1000
52-week range2.5000 - 6.7900
Volume16,038,200
Avg. volume3,842,072
Market cap934.791M
Beta (5Y monthly)1.40
PE ratio (TTM)N/A
EPS (TTM)-1.1310
Earnings date27 Oct 2021 - 01 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est10.00
  • Motley Fool

    Here's Why Agenus Stock Is Getting Hammered Today

    The company's experimental anti-PD1 drug hit a wall.

  • GlobeNewswire

    Agenus Provides Update on Balstilimab Development

    Company voluntarily withdraws BLA at FDA’s recommendation following full approval of pembrolizumab, which came four months earlier than FDA goal dateBalstilimab achieved trial endpoints with 20% response rates in PD-L1 positive patients, versus 14% reported in pembrolizumab’s label; Agenus successfully completed 3 FDA pre-approval inspections for the PDUFA date of Dec. 16, 2021Agenus plans to launch expanded access programs to give patients access to balstilimab in several countries, including t

  • GlobeNewswire

    Agenus to Receive $20M Milestone Payment from Bristol Myers Squibb with Dosing of First Patient with its TIGIT Bispecific Antibody

    LEXINGTON, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it has triggered the first development milestone payment under its global licensing agreement with Bristol Myers Squibb for AGEN1777, an Fc-enhanced bispecific anti-TIGIT antibody. Agenus will receive a $20 million cash